(S1 (S (NP (NP (NN Analysis)) (PP (IN of) (NP (NP (NN Akt)) (, ,) (NP (NN NFkappaB)) (, ,) (CC and) (NP (NN Stat3) (NNS Pathways)))) (PP (IN in) (NP (NP (NN Contribution)) (PP (TO to) (NP (NP (DT the) (NP (NP (NN Growth)) (CC and) (NP (NN Survival)))) (PP (IN of) (NP (NN Lymphoma) (NNS Cells))))))))))
(S1 (S (NP (NP (-LRB- -LRB-) (NN A-D) (-RRB- -RRB-) (NN Immunoblot) (NN analysis)) (PP (IN of) (NP (JJ wild-type) (CC and) (NN LMP1) (JJ transgenic) (NNS lymphomas))) (PP (IN for) (NP (NP (NP (NN Akt)) (, ,) (NP (NN NFkappaB)) (, ,) (CC and) (NP (NN Stat3) (NN signaling))) (PP (IN after) (NP (NP (NN treatment)) (PP (IN with) (NP (LST (-LRB- -LRB-) (LS A) (-RRB- -RRB-)) (NP (NP (DT an) (NN Akt) (NN inhibitor)) (, ,) (NP (NP (NP (NP (NN triciribine)) (, ,) (NP (LST (-LRB- -LRB-) (LS B) (-RRB- -RRB-)) (NP (DT an) (NN NFkappaB) (NN inhibitor)) (, ,) (NP (CD BAY11-7085))) (, ,) (CC and) (NP (DT the) (NN Stat3) (NNS inhibitors))) (PRN (-LRB- -LRB-) (NP (NN C)) (-RRB- -RRB-))) (NN cucurbitacin) (NN I))) (CC and) (LST (-LRB- -LRB-) (LS D) (-RRB- -RRB-)) (CD AG490))))) (, ,) (PP (IN at) (NP (DT the) (VBN indicated) (NNS concentrations))))) (. .))))
(S1 (S (S (NP (NNS Arrows)) (VP (VBP indicate) (NP (NP (DT the) (NNS positions)) (PP (IN of) (NP (NP (NP (NP (NN alpha)) (CC and) (NP (NN beta))) (NNS isoforms)) (PP (IN of) (NP (NN Stat3)))))))) (. .)))
(S1 (S (S (NP (NN Actin)) (VP (VBD was) (VP (VBN used) (PP (IN as) (NP (DT a) (NN loading) (NN control)))))) (. .)))
